HRT for Menopause: Types, Benefits, Risks, and How to Decide

HRT for Menopause: It’s Time to Revisit What You’ve Been Told

Hormone replacement therapy, now more often called menopausal hormone therapy (MHT) or hormone therapy (HT), is the most effective treatment available for hot flashes, night sweats, and the related symptoms of menopause, and two decades of follow-up research show the heart attack and breast cancer warnings that came out of the 2002 Women’s Health Initiative (WHI) trial were overstated for most women considering it today.

For millions of women, menopause brings symptoms that range from annoying to life-disrupting. Hot flashes that wake you at 3 a.m. soaked in sweat. Brain fog that makes you forget words mid-sentence. Mood swings that feel completely out of character. Vaginal dryness that makes intimacy painful. Joint aches that showed up out of nowhere.

Hormone replacement therapy can treat all of these symptoms effectively. Yet since 2002, when the Women’s Health Initiative (WHI) study made headline news, millions of women have been told HRT is too dangerous, or have been too afraid to ask about it. Doctors stopped prescribing it. Women stopped requesting it. And a generation of women suffered through menopause unnecessarily.

The tragedy is that the original WHI headlines were misleading. Two decades of follow-up data, reanalysis, and new research have painted a very different picture. This guide will walk you through what we know now, so you can have a real conversation with your doctor based on evidence, not fear.

Understanding Your HRT Options

Not all HRT is the same. The type of hormone, the delivery method, and whether you need estrogen alone or estrogen plus a progestogen all affect both benefits and risks. Let’s break it down.

Estrogen-Only vs. Combined HRT

Estrogen-only therapy (ET) is appropriate for women who have had a hysterectomy. Without a uterus, there’s no risk of endometrial cancer from unopposed estrogen, so progesterone isn’t needed for uterine protection.

Combined therapy (EPT) pairs estrogen with a progestogen and is necessary for women who still have their uterus. Estrogen alone stimulates the uterine lining, and without a progestogen to counterbalance that effect, the risk of endometrial hyperplasia and cancer increases significantly. The progestogen can be given continuously (daily) or cyclically (10 to 14 days per month).¹

Types of Estrogen

• Estradiol (17-beta estradiol): Bioidentical, meaning it’s structurally identical to the estrogen your ovaries produced. Available as patches (Vivelle-Dot, Climara), gels (EstroGel, Divigel), sprays (Evamist), and oral tablets (Estrace).
• Conjugated equine estrogens (CEE): Derived from pregnant mare urine. The brand name is Premarin. This was the estrogen used in the WHI study. It contains a mix of estrogens, some of which are not found in the human body.
• Conjugated estrogens/bazedoxifene (Duavee): A tissue-selective estrogen complex that pairs CEE with a SERM (selective estrogen receptor modulator), eliminating the need for a separate progestogen.

Types of Progestogens

• Micronized progesterone (Prometrium): Bioidentical. Derived from plant sources and processed to match human progesterone. Evidence suggests it carries a lower breast cancer risk than synthetic progestins.²
• Medroxyprogesterone acetate (MPA/Provera): The synthetic progestin used in the WHI. Associated with a small increase in breast cancer risk when combined with CEE.
• Norethindrone acetate: Another synthetic progestin, available alone or combined with estradiol in various formulations.
• Levonorgestrel IUD (Mirena): Can provide local endometrial protection while allowing systemic estrogen. Some women prefer this approach because it avoids systemic progestogen side effects like bloating and mood changes.

Delivery Methods: Why Route Matters

This is one of the most important and underappreciated aspects of HRT. How estrogen enters your body changes its risk profile.

Transdermal (Patches, Gels, Sprays)

When estrogen is absorbed through the skin, it enters the bloodstream directly without first passing through the liver. This matters because oral estrogen’s “first pass” through the liver increases the production of clotting factors, C-reactive protein, and triglycerides. Transdermal estradiol avoids these liver effects.

The clinical implications are significant. The ESTHER study, a French case-control study, found that transdermal estrogen was not associated with increased venous thromboembolism (blood clots), while oral estrogen was.³ For women who are overweight, have a history of migraines with aura, or carry clotting risk factors, transdermal is the preferred route.

Oral

Oral estrogen is effective and well-studied, but the first-pass liver effect means higher clotting risk. Oral micronized progesterone (Prometrium) is commonly prescribed and well-tolerated. Many clinicians recommend taking it at bedtime because it has a mild sedative effect that can improve sleep.

Pellet Implants

Subcutaneous pellets are inserted every 3 to 6 months and provide steady hormone levels. They’re popular in integrative and functional medicine practices. The advantage is consistency. The disadvantage is that if you experience side effects, you can’t quickly reduce the dose.

Vaginal (Local)

Low-dose vaginal estrogen (creams, rings, tablets) treats genitourinary symptoms with minimal systemic absorption. The Endocrine Society and North American Menopause Society consider vaginal estrogen safe even for many women with a history of breast cancer, though oncologist consultation is recommended. These preparations are so low-dose that most women don’t even need a progestogen alongside them.⁴

Comparing Delivery Routes at a Glance

The table below summarizes how the main delivery routes differ once the liver first-pass effect and clotting data are taken into account.

The WHI Study: What Actually Happened

In July 2002, the WHI estrogen-plus-progestin trial was stopped early. Headlines screamed that HRT caused breast cancer and heart attacks. Women flushed their prescriptions down the toilet. Doctors stopped writing them. It was, by many accounts, a public health overcorrection of historic proportions.

Here’s what those headlines left out:

The study population was not representative of typical HRT users. The average age of participants was 63. Most were more than a decade past menopause. Many had pre-existing cardiovascular risk factors. In clinical practice, HRT is typically started during the menopausal transition or shortly after, not at 63.⁵

The absolute risk increase was small. The often-cited “26% increase in breast cancer” was a relative risk. In absolute terms, this translated to about 8 additional breast cancer cases per 10,000 women per year. To put that in perspective, that’s a risk increase similar to drinking one to two glasses of wine per day, or being obese.⁵

The estrogen-only arm told a different story. Women who took conjugated equine estrogen without a progestin (because they’d had a hysterectomy) actually had a lower rate of breast cancer than the placebo group. After 18 years of follow-up, this finding held up. Estrogen alone was not the villain.⁶

Younger women fared better. When researchers stratified results by age, women aged 50 to 59 who started HRT showed a trend toward reduced cardiovascular events. The increased cardiac risk was concentrated in women who started HRT in their 60s and 70s, well past the optimal window.⁷

The Timing Hypothesis: When You Start Matters

The “timing hypothesis” or “window of opportunity” concept has become central to modern HRT prescribing. The idea is straightforward: estrogen is protective for blood vessels that are still healthy, but potentially harmful for vessels that already have significant atherosclerotic plaque.

When a woman starts HRT within 10 years of menopause onset, or before age 60, estrogen appears to maintain arterial flexibility, reduce plaque formation, and support endothelial function. When started late, after atherosclerosis is already established, estrogen may destabilize existing plaques.

The ELITE trial (Early versus Late Intervention Trial with Estradiol) provided direct evidence for this. Women who started estradiol within 6 years of menopause had significantly less progression of carotid artery thickness compared to placebo. Women who started more than 10 years after menopause showed no such benefit.⁸

The Danish Osteoporosis Prevention Study (DOPS) followed women for 16 years who started HRT early in menopause. They had significantly reduced risk of heart failure, heart attack, and death, with no increase in cancer, blood clots, or stroke.⁹

Benefits Beyond Hot Flashes

Menopause isn’t just about hot flashes. Estrogen receptors exist throughout the body, and estrogen withdrawal affects virtually every organ system. Here’s what HRT can do beyond temperature regulation.

Bone Health

Estrogen is the primary regulator of bone turnover in women. The accelerated bone loss of the first 5 to 10 years after menopause is directly caused by estrogen deficiency. HRT prevents this loss and reduces fracture risk, including hip fractures, which carry significant mortality in older women.⁵

Cardiovascular Protection (When Timed Right)

As discussed above, early initiation of HRT appears to be cardioprotective. Estrogen supports endothelial function, improves lipid profiles (raising HDL, lowering LDL), and reduces arterial stiffness. The cardiovascular benefits are most pronounced with transdermal estradiol.

Cognitive Health

The brain is rich in estrogen receptors, especially the hippocampus (memory center) and prefrontal cortex (executive function). Observational studies consistently show that women who use HRT starting in early menopause have lower rates of Alzheimer’s disease. The WHIMS (Women’s Health Initiative Memory Study) found increased dementia risk, but those women were 65 and older at initiation. Once again, timing appears to be everything.

Mood and Mental Health

Perimenopause and early menopause carry elevated risk for depression, anxiety, and irritability. Estradiol has been shown to improve depressive symptoms during the menopausal transition, sometimes more effectively than SSRIs for hormone-related mood changes.

Genitourinary Health

Vaginal atrophy, also called genitourinary syndrome of menopause, along with recurrent urinary tract infections, urinary urgency, and painful intercourse, are all estrogen-responsive conditions. Left untreated, these symptoms tend to worsen over time (unlike hot flashes, which often diminish). Local or systemic estrogen can reverse these changes.

Joint and Muscle Health

Many women notice joint pain and stiffness around menopause. Estrogen has anti-inflammatory effects on joints, and HRT users report less musculoskeletal pain. Estrogen also supports muscle mass and strength, which becomes increasingly important for fall prevention as women age.

Skin, Hair, and Collagen

Estrogen supports collagen production and skin hydration, and collagen loss accelerates in the years immediately after menopause, contributing to thinner, less elastic skin and changes in hair density. HRT can slow this decline, though it is not marketed or studied as a cosmetic treatment. Some women pair hormone therapy with adjunctive skin care approaches such as red light therapy for skin, which works through a different mechanism and does not require a prescription.

How Long Should You Stay on HRT?

There is no fixed stop age or mandatory duration written into the guidelines. According to the 2022 NAMS position statement, the decision to continue hormone therapy should be individualized and reassessed on a regular basis rather than tied to an arbitrary calendar limit.¹

For most women who start within the window of opportunity, that means continuing for as long as symptoms persist and the benefit-risk balance stays favorable, with an annual conversation with a clinician, often a gynecologist, menopause specialist, or endocrinologist, about whether to continue, adjust the dose, or taper off. Women with premature ovarian insufficiency or early surgical menopause are generally advised to continue hormone therapy at least until the average age of natural menopause, around 51, to replace hormones the body would otherwise still be producing.

If you decide to stop, a gradual taper over several weeks to months tends to produce fewer rebound hot flashes than stopping abruptly, though either approach is medically reasonable. A menopause specialist can help build a taper schedule suited to your symptoms and health history.

Understanding Risks by Delivery Method and Formulation

The risk picture depends heavily on what you take and how you take it. Here’s a summary of the current evidence:

• Venous thromboembolism (blood clots): Increased with oral estrogen. Not increased with transdermal estradiol.³
• Stroke: Slightly increased with oral estrogen, particularly at higher doses. Risk appears lower with transdermal delivery and lower doses.
• Breast cancer: Estrogen alone does not increase risk (and may decrease it). Combined therapy with synthetic progestins (MPA) increases risk modestly after 3 to 5 years. Combined therapy with micronized progesterone appears to carry lower risk.²
• Endometrial cancer: Increased with unopposed estrogen in women with a uterus. Eliminated by appropriate progestogen use.
• Gallbladder disease: Increased with oral estrogen. Not increased with transdermal delivery.

HRT After Hysterectomy, Early Menopause, and Other Special Situations

Standard HRT guidance assumes a woman going through natural menopause at a typical age, but several situations change the calculation.

Surgical Menopause

Women who have both ovaries removed (bilateral oophorectomy) experience an abrupt drop in estrogen rather than the gradual decline of natural menopause, which can produce more severe vasomotor and mood symptoms. Because these women typically have the uterus removed at the same surgery, estrogen-only therapy is usually appropriate. Read more in our guide to surgical menopause.

Premature Ovarian Insufficiency and Early Menopause

Women who reach menopause before age 40 (premature ovarian insufficiency) or between ages 40 and 45 (early menopause) face a longer stretch of estrogen deficiency and a higher lifetime risk of osteoporosis and cardiovascular disease if left untreated. For this group, hormone therapy is generally recommended rather than optional, continuing until at least the average age of natural menopause.

Perimenopause

Hormone levels during perimenopause fluctuate rather than decline steadily, which is why some women need a different approach, such as low-dose birth control or cyclic progestogen, before transitioning to standard postmenopausal HRT. Our perimenopause guide covers how symptoms and treatment differ during this transitional stage.

Non-Hormonal and Complementary Approaches

HRT is not the only option, and it is not appropriate for every woman. For those with a personal history of hormone-receptor-positive breast cancer, a recent blood clot, or who simply prefer to avoid hormones, several non-hormonal options target menopause symptoms through different mechanisms.

Low-dose SSRIs and SNRIs, originally developed for depression and anxiety, can reduce hot flash frequency and severity for some women. Gabapentin, typically used for nerve pain, has similar evidence for nighttime hot flashes and sleep disruption. Newer non-hormonal medications that act on the brain’s temperature-regulating pathway are also available by prescription and do not carry the clotting or hormone-sensitive cancer considerations that come with estrogen.

Lifestyle measures, including regular exercise, layered clothing, cooling the bedroom, and limiting alcohol and spicy food triggers, can meaningfully reduce hot flash burden even when used alongside HRT. Cognitive behavioral therapy has evidence for reducing the distress associated with hot flashes, independent of their frequency. Some women also explore menopause supplements, though the evidence base for most of these is far thinner than for prescription hormone therapy or the non-hormonal medications above, and supplement quality and dosing are not standardized the way prescription drugs are.

These approaches are not a substitute for a personalized conversation about whether HRT is right for you. They are evidence that effective menopause care exists for women who cannot or choose not to take hormones.

How to Talk to Your Doctor

If you’re considering HRT, here are questions worth bringing to your appointment:

• “Based on my age, time since menopause, and health history, am I in the window where HRT benefits are likely to outweigh risks?”
• “Would transdermal estradiol with micronized progesterone be appropriate for me?”
• “What monitoring do you recommend once I start?”
• “How long is it reasonable for me to continue HRT?”
• “Are there any personal risk factors (family history, clotting disorders, breast cancer history) that change the calculation for me?”

If your provider dismisses HRT outright without discussing your individual risk profile, it may be worth seeking a second opinion from a menopause specialist. The North American Menopause Society maintains a directory of certified menopause practitioners.

You can also research hormone therapy providers directly through the HRT clinic directory, which lists hormone therapy practices by location, or review the fundamentals in the HRT treatment guide before your appointment.

How to Decide: A Framework

There’s no single right answer. But here’s a practical framework:

HRT is most clearly beneficial when:

• You’re experiencing moderate to severe vasomotor symptoms.
• You’re under 60 or within 10 years of menopause onset.
• You have no personal history of breast cancer, stroke, or blood clots.
• You have risk factors for osteoporosis.
• You have premature ovarian insufficiency (menopause before 40).

HRT requires careful individualized assessment when:

• You have a family history of breast cancer.
• You’re between 60 and 70 and want to start for the first time.
• You have cardiovascular risk factors.
• You have a history of migraines with aura (transdermal preferred).

HRT is generally not recommended when:

• You have a personal history of hormone-receptor-positive breast cancer.
• You’ve had a recent stroke, heart attack, or blood clot.
• You have active liver disease.
• You have unexplained vaginal bleeding (needs a postmenopausal bleeding workup first).

The Bottom Line

The science on HRT has evolved dramatically since 2002. We now know that the type of hormone, the route of delivery, the timing of initiation, and the patient’s individual risk profile all matter enormously. Blanket statements that HRT is “dangerous” are not supported by the modern evidence base.

For the right woman at the right time, HRT is the single most effective treatment for menopause symptoms, and it may offer long-term benefits for bones, brain, and heart. You deserve to make this decision with full information, not based on 20-year-old headlines.

To restate the core finding plainly: menopausal hormone therapy, started within about 10 years of your final period or before age 60, remains the most effective treatment for moderate to severe hot flashes and night sweats, and the absolute risks for most healthy women in that window are small.¹

For more on how menopause affects your body and the full range of treatment options, visit our Menopause pillar page.

Frequently Asked Questions

Does HRT actually work for menopausal symptoms?

According to this guide, HRT is the most effective treatment for menopausal vasomotor symptoms, meaning hot flashes and night sweats. The article also lists bone protection, cardiovascular support, cognitive health, and improved quality of life among its potential benefits.

What did the Women’s Health Initiative (WHI) study really find about breast cancer risk?

The guide reinterprets the WHI findings, noting the absolute breast cancer risk increase was about 8 additional cases per 10,000 women per year. It points out the study population averaged age 63, more than a decade past menopause, and that the estrogen-only arm actually showed a lower rate of breast cancer than the placebo group.

Does the age I start HRT matter?

Yes, the article describes a timing hypothesis in which the optimal window is within 10 years of menopause onset or before age 60. It cites the ELITE trial, where women starting within 6 years had significantly less progression of carotid artery thickness, and the DOPS study, where early HRT users showed significantly reduced risk of heart failure, heart attack, and death.

Is a patch safer than a pill?

The guide notes meaningful differences by delivery method. Transdermal (patch) estrogen is not associated with increased venous thromboembolism, while oral estrogen is associated with increased blood clots per the ESTHER study. It also states that micronized progesterone carries a lower breast cancer risk than synthetic progestins such as MPA.

What are the risks and side effects of HRT?

The article lists venous thromboembolism (oral route), stroke (oral, higher doses), breast cancer (with synthetic progestins after 3 to 5 years), gallbladder disease (oral only), and endometrial cancer, which it notes is prevented by an appropriate progestogen. It frames these risks as reasons the decision requires careful, individualized assessment.

Who is HRT recommended for, and who should avoid it?

Per the guide, HRT is most clearly beneficial for women with moderate to severe vasomotor symptoms who are under 60 or within 10 years of menopause, have no personal history of breast cancer, stroke, or blood clots, and have osteoporosis risk factors. It is generally not recommended for those with a personal history of hormone-receptor-positive breast cancer, a recent stroke, heart attack, or blood clot, or active liver disease.

Are there alternatives if I can’t take HRT?

Yes. Non-hormonal prescription options, including certain SSRIs, SNRIs, gabapentin, and newer non-hormonal medications for hot flashes, can help women with a history of hormone-sensitive cancer or blood clots, or who prefer to avoid hormones. Lifestyle changes and cognitive behavioral therapy also reduce hot flash frequency and distress, though the evidence base is generally less robust than for hormone therapy itself.

Sources

1. The NAMS 2022 Hormone Therapy Position Statement Advisory Panel. The 2022 hormone therapy position statement of The North American Menopause Society. Menopause. 2022;29(7):767-794. doi:10.1097/GME.0000000000002028 ↩
2. Fournier A, Berrino F, Clavel-Chapelon F. Unequal risks for breast cancer associated with different hormone replacement therapies: results from the E3N cohort study. Breast Cancer Res Treat. 2008;107(1):103-111. doi:10.1007/s10549-007-9523-x ↩
3. Canonico M, Oger E, Plu-Bureau G, et al. Hormone therapy and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration and progestogens: the ESTHER study. Circulation. 2007;115(7):840-845. doi:10.1161/CIRCULATIONAHA.106.642280 ↩
4. The American College of Obstetricians and Gynecologists Committee Opinion No. 659. The use of vaginal estrogen in women with a history of estrogen-dependent breast cancer. Obstet Gynecol. 2016;127(3):e93-e96. doi:10.1097/AOG.0000000000001351 ↩
5. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s Health Initiative randomized controlled trial. JAMA. 2002;288(3):321-333. doi:10.1001/jama.288.3.321 ↩
6. LaCroix AZ, Chlebowski RT, Manson JE, et al. Health outcomes after stopping conjugated equine estrogens among postmenopausal women with prior hysterectomy: a randomized controlled trial. JAMA. 2011;305(13):1305-1314. doi:10.1001/jama.2011.382 ↩
7. Manson JE, Chlebowski RT, Stefanick ML, et al. Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women’s Health Initiative randomized trials. JAMA. 2013;310(13):1353-1368. doi:10.1001/jama.2013.278040 ↩
8. Hodis HN, Mack WJ, Henderson VW, et al. Vascular effects of early versus late postmenopausal treatment with estradiol. N Engl J Med. 2016;374(13):1221-1231. doi:10.1056/NEJMoa1505241 ↩
9. Schierbeck LL, Rejnmark L, Tofteng CL, et al. Effect of hormone replacement therapy on cardiovascular events in recently postmenopausal women: randomised trial. BMJ. 2012;345:e6409. doi:10.1136/bmj.e6409 ↩
10. Stuenkel CA, Davis SR, Gompel A, et al. Treatment of symptoms of the menopause: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2015;100(11):3975-4011. doi:10.1210/jc.2015-2236
11. Menopause: The Complete Guide
12. Bioidentical Hormone Therapy (BHRT): Benefits, Risks, and Who It’s For
13. Hormone Replacement Therapy Pillar Page
14. Hashimoto’s Symptoms: What Your Thyroid Is Trying to Tell You
15. Red Light Therapy for Skin: What the Research Shows